Amneal Pharmaceuticals, Inc.
AMRX
Xếp hạng trong cổ phiếu
#3002
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Giá cổ phiếu
$19.07
Đồng bộ lần cuối: 2026-10-16
Vốn hóa thị trường
$6.09B
Thay đổi (1 ngày)
-0.94%
Thay đổi (1 năm)
92.24%
Quốc gia
US
Giao dịch Amneal Pharmaceuticals, Inc. (AMRX)
Danh mục
Healthcare
EPS của Amneal Pharmaceuticals, Inc. (AMRX)
EPS tính đến June 2026 TTM: $0.50
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Amneal Pharmaceuticals, Inc., EPS hiện tại của công ty (TTM) là $0.50. Vào cuối năm 2023, công ty có EPS là $-0.48, giảm so với EPS năm 2022 là $-0.86.
Lịch sử EPS của Amneal Pharmaceuticals, Inc. từ 2014 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| 2026 (TTM) | $0.50 | -231.58% |
| 2024 | $-0.38 | -20.83% |
| 2023 | $-0.48 | -44.19% |
| 2022 | $-0.86 | -1,328.57% |
| 2021 | $0.07 | -88.71% |
| 2020 | $0.62 | -113.57% |
| 2019 | $-4.57 | 243.61% |
| 2018 | $-1.33 | -191.10% |
| 2017 | $1.46 | 32.73% |
| 2016 | $1.10 | 22.22% |
| 2015 | $0.90 | -4.26% |
| 2014 | $0.94 | 0.00% |
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 11.26% |
IN
|
